【摘要】

目的：分析齐拉西酮联合心境稳定剂治疗双相躁狂发作患者对临床疗效、BPRS评分及安全性的影响。
方法：选择双相躁狂发作患者，共计60例，随机分成研究组、对照组，分别使用齐拉西酮合并碳酸锂/丙戊酸钠治疗、奥氮平联合碳酸锂/丙戊酸钠治疗。分析组间患者治疗第1、2周BPRS总分评定情况、副作用（头晕、嗜睡、静坐不能）发生率、治愈率。
结果：研究组治疗第1、2周BPRS总分评定情况、副作用（头晕、嗜睡、静坐不能）发生率、治愈率与对照组数据指标差异明显，且研究组各项数据指标更优，P＜0.05。
结论：齐拉西酮联合心境稳定剂治疗双相躁狂发作患者的临床疗效显著，使用安全性更高

【Abstract】

Objective: to analyze the clinical efficacy, BPRS score and safety of ziprasidone combined with mood stabilizer in the treatment of bipolar manic episodes.
Methods: a total of 60 patients with bipolar manic seizures were randomly divided into study group and control group, which were treated with olanzapine combined with lithium carbonate / valproate, olanzapine combined with sodium valproate. The total score of BPRS and the incidence of side effects (dizziness, lethargy, sedentary inability) and cure rate were analyzed in first, second weeks.
Results: the rate of BPRS total score, the incidence of side effects (dizziness, lethargy, sitting inability) and the cure rate of the study group were significantly different from those of the control group for first, second weeks, and the data of the study group were better than those in the study group, P < 0.05.
Conclusion  : ziprasidone combined with mood stabilizer is effective and safe in the treatment of bipolar manic episodes.